PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.
PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee:
BOSTON, July 15, 2025 /PRNewswire/ -- Schneider Electric, the global leader in the digital transformation of energy management and automation, today announced the launch of...
Zinzino group revenue increased 56% in Q2, compared with the previous year.
GOTHENBURG, Sweden, July 3, 2025 /PRNewswire/ -- The revenue in June for Zinzino's sales...